Incyte Corporation

Incyte Corporation operates as a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases. The company’s products include INCB18424 (Oral), which is in Phase IIa clinical trials for the treatment of myelofibrosis, rheumatoid arthritis, refractory prostate cancer, and multiple myeloma, as well as for the treatment of psoriasis in a Phase I clinical trial; INCB18424 (Topical), which is in a Phase IIa clinical trial for the treatment of Psoriasis; and INCB28050, a preclinical stage drug for the treatment of rheumatoid arthritis. Its products also include INCB13739, which is in a Phase IIa clinical trial for the treatment of Type 2 Diabetes; and INCB20817, which is in a Phase I clinical trials for the treatment of Type 2 Diabetes. In addition, the company’s products include INCB19602 in Phase I clinical trial for the treatment of Type 2 Diabetes; INCB9471 in Phase II clinical trial for the treatment of HIV; INCB15050 in Phase I clinical trial for the treatment of HIV; INCB7839 in Phase IIa clinical trial for the treatment of solid tumors, and Phase II clinical trial for the treatment of breast cancer; and INCB8696 in Phase I clinical trial for the treatment of multiple sclerosis. Further, its pre-clinical stage products involves in the treatment of oncology disease. The company has a collaborative research and license agreement with Pfizer, Inc. for the pursuit of its CCR2 antagonist program. It offers its products in the United States, Canada, Germany, Sweden, and the United Kingdom. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.